Collaborations

Development Partners

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH)

Uni Pharma Co., LTD

In June 2010, Raptor entered into an exclusive agreement with Uni Pharma, to commercialize Convivia™ in Taiwan, with an option for South Korea. Uni Pharma will be responsible for clinical development, registration, and commercialization of Convivia™ in these markets. Raptor expects this to be the first in a franchise of out-licensing transactions to develop Convivia™ throughout Asia.

Academic Collaborations

Raptor works with several leading research institutions and nonprofit organizations as part of our efforts to expand the reach and benefit of established therapeutics.

University of California, San Diego (UCSD) Medical Center

On December 17, 2007, we acquired an exclusive worldwide license for Delayed-Release cysteamine bitartrate (DR Cysteamine, including RP103 and RP104), a clinical product candidate. We have collaborated with clinicians at UCSD in studies for the RP103 and RP104 programs in nephropathic cystinosis and NASH. Raptor's license also covers other indications in which cysteamine has been studied, including Huntington’s Disease and schizophrenia.

Johns Hopkins University

Raptor has an exclusive license agreement with Johns Hopkins University (JHU) for intellectual property related to the novel use of glutamate receptor antagonists, including oral tezampanel, for the prevention and treatment of stroke, heart attack and other conditions associated with increased platelet aggregation. The intellectual property is based on research conducted in the JHU laboratories of Craig Morrell, D.V.M., Ph.D., and Charles Lowenstein, M.D., that demonstrates the importance of glutamate release in promoting platelet activation and thrombosis and which identifies the AMPA receptors on platelets as a new antithrombotic target.

Washington University, St. Louis

Raptor maintains a license through the technology office at Washington University in St. Louis for the Mesd technology we use in our WntTide™ program for oncology applications. This technology was developed in the labs of Dr. Bu, professor of Pediatrics and Cell Biology and Physiology. Dr. Bu is a member of Raptor's Advisory Board.

Centre Hospitalier Universitaire d'Angers (CHU d'Angers)

Raptor is collaborating with CHU d'Angers in a Phase 2 study of RP103 in Huntington's Disease. The French Ministry of Health is providing a grant that supports the two-year, multi-center study. CHU d'Angers and the Curie Institute collaborated on the protocol, advancing preclinical work by scientists at the Curie Institute.

University of Iowa

Raptor has licensed patents from the University of Iowa covering the intrathecal administration of tezampanel to treat chronic pain. In collaboration with academic collaborators in Iowa and at the University of California, San Diego, Raptor will leverage the extensive regulatory and manufacturing history of tezampanel to efficiently move into the clinic with this novel indication.

University of Arizona

Raptor has licensed intellectual property from the University of Arizona covering metabolic markers of hepatic disorders for possible application in diagnosing and monitoring NASH and other liver disorders. Raptor intends to develop this diagnostic application in conjunction with its clinical development program in NASH.

Major Patient Advocacy Partners

The Cystinosis Foundation

The Cystinosis Foundation is an all-volunteer, nonprofit organization dedicated to providing services for those suffering from cystinosis through parental support, education, research support and affiliations. Raptor has an informal and ongoing collaboration with the Cystinosis Foundation to further patient care and education.

The Cystinosis Research Foundation (CRF)

The Cystinosis Research Foundation (Natalie's Wish) is dedicated to finding better treatments to improve the quality of life for those with cystinosis and to finding a cure for this devastating disease through research support and education. Raptor collaborates with CRF in a variety of ways to improve the standard of care for cystinosis sufferers and their families.

The Cystinosos Research Network (CRN)

The Cystinosis Research Network is an all-volunteer, non-profit organization dedicated to supporting and advocating research, providing family assistance and educating the public and medical communities about Cystinosis. The vision of the Cystinosis Research Network is the discovery of improved treatments and ultimately a cure for Cystinosis.

The Huntington's Disease Society of America (HDSA)